{"disease":{"id":"ankylosing-spondylitis-as","name":"ankylosing spondylitis as"},"drugs":{"marketed":[{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and ankylosing spondylitis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and rheumatoid arthritis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and rheumatoid arthritis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and Crohn's disease and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and ankylosing spondylitis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis, ankylosing spondylitis, and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and ankylosing spondylitis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and ankylosing spondylitis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and rheumatoid arthritis and ankylosing spondylitis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, and atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, atopic dermatitis, and plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":25,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06568029","title":"Construct Validity and Responsiveness of EQ-5D-3L in Patients With Rheumatic Disease","phase":"","overall_status":"COMPLETED","enrollment_count":77651,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT06766552","title":"A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04402086","title":"Rheumatology Patient Registry and Biorepository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT06988813","title":"Bidirectional Cohort Study of Nanfang Spondyloarthritis","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT05883371","title":"IMPACT - AndHealth Autoimmune Research Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"AndHealth","has_results":false},{"nct_id":"NCT04541810","title":"A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":2369,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT06844643","title":"The Disease Progression of Chinese Axial Spondyloarthritis in a Real-word Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":2250,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT05190484","title":"bIosimilar of aDalimumab, an European evAluation","phase":"","overall_status":"UNKNOWN","enrollment_count":1050,"lead_sponsor_name":"Fresenius Kabi","has_results":false},{"nct_id":"NCT03729674","title":"Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT03074656","title":"The Norwegian Drug Monitoring Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Diakonhjemmet Hospital","has_results":false},{"nct_id":"NCT02466217","title":"Phenomics in Autoimmune and Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":537,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02750800","title":"Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)","phase":"","overall_status":"COMPLETED","enrollment_count":427,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT06707194","title":"Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT05913817","title":"The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.","phase":"","overall_status":"COMPLETED","enrollment_count":324,"lead_sponsor_name":"Jamp Pharma Corporation","has_results":false},{"nct_id":"NCT05427942","title":"Yuflyma® (Adalimumab), Patient Experience After Switching","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Celltrion HealthCare France","has_results":false},{"nct_id":"NCT07329556","title":"Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Bursa City Hospital","has_results":false},{"nct_id":"NCT03339089","title":"Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":224,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04018599","title":"Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"Fresenius Kabi SwissBioSim GmbH","has_results":false},{"nct_id":"NCT07509775","title":"Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis (AS): A Cohort Study Protocol Focusing on Spondyloarthritis Research Consortium of Canada (SPARCC) Scoring System","phase":"","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT06888973","title":"Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases","phase":"PHASE1, PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","has_results":false},{"nct_id":"NCT04924270","title":"Safety and Efficacy of Capsule FMT in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT03178487","title":"A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":187,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT06873074","title":"A Retrospective Cohort Study About Surgical Efficacy for Lower Cervical Fractures in Ankylosing Spondylitis","phase":"","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"Zhou Fang","has_results":false},{"nct_id":"NCT07117344","title":"Biomarkers in Ankylosing Spondylitis","phase":"","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Kirsehir Ahi Evran Universitesi","has_results":false},{"nct_id":"NCT02047110","title":"BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02988674","title":"A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation","phase":"","overall_status":"COMPLETED","enrollment_count":139,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04751396","title":"Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors","phase":"","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03223012","title":"Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service","phase":"","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03941184","title":"Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05715463","title":"Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":101,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05303285","title":"A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT01768858","title":"Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT07383805","title":"Expression of Tim-3 on Neutrophils in Ankylosing Spondylitis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":81,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT01988506","title":"Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06967883","title":"Ultrasound Assessment of Neck Muscles and Balance in Male Patients With Ankylosing Spondylitis","phase":"","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"Istanbul Physical Medicine Rehabilitation Training and Research Hospital","has_results":false},{"nct_id":"NCT07327073","title":"The Effect of Exercise on Serum Irisin Levels and Clinical Parameters in Patients With Axial Spondyloarthritis.","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":75,"lead_sponsor_name":"Kirsehir Ahi Evran Universitesi","has_results":false},{"nct_id":"NCT03357471","title":"Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true},{"nct_id":"NCT04839315","title":"COVID-19 Vaccination in Rheumatic Disease Patients","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":58,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05968469","title":"The Effects of Aerobic Exercise in Patients With Ankylosing Spondylitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Afyonkarahisar Health Sciences University","has_results":false},{"nct_id":"NCT04885751","title":"Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Seoul National University Boramae Hospital","has_results":false},{"nct_id":"NCT03329885","title":"A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":38,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT06688929","title":"Psychosocial and Functional Factors in AxSpA","phase":"","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Universidad de Extremadura","has_results":false},{"nct_id":"NCT07262294","title":"Deep Breathing Combined With Core Stability Exercises in the Treatment of Patients With Ankylosing Spondylitis","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT06226792","title":"Muscle Architecture in Ankylosing Spondylitis","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Bezmialem Vakif University","has_results":false},{"nct_id":"NCT03505892","title":"A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)","phase":"","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03322618","title":"Evaluation of the Expression and Functions of the KIR3DL2 Receptor and the Anti-inflammatory Activity of IPH4102 in Blood Samples","phase":"NA","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT05115370","title":"Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University of Nottingham","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}